Established in 2000, Sichuan Credit Pharmaceutical Co., Ltd. is a new high-tech enterprise integrating research & development, production and sales. With a covering area of 260Mu, it is located in No.8, Jiuxiang Avenue, Pharmaceutical Industry Park of National High-tech Zone, Luzhou City, Sichuan Province, and now, it possesses the production lines respectively for capsules, tablets, freeze-dried powder injections, liquid injections, anti-tumor solid preparations, and Chinese medicine extractions.
The Company focuses on the research & development, production and sales of central nervous system disease drugs. It administrates Sichuan Credit ChemWerth Pharmaceutical Co., Ltd., Sichuan Zhongling chaungtuo Pharmaceutical Technology Co., Ltd., Feidelidi Biopharmaceutical (America) Co., Ltd., jointly invested by China and USA and Sichuan CreditMedeia Medical Equipment co., Ltd.
In July 2007, the Company and ChemWerth jointly established Sichuan Credit ChemWerth Pharmaceutical Co., Ltd., to specialize in BPC research & development, production and sales. In December 2010, Credit ChemWerth passed American FDA certificate for the first time; its products have been sold to European and American markets, and it has become the first enterprise of Sichuan Province to export human BPCs to European and American markets.